Study protocol of the TEC-ORL clinical trial: a randomized comparative phase II trial investigating the analgesic activity of capsaicin vs Laroxyl in head and neck Cancer survivors presenting with neuropathic pain sequelae.
Head and neck survivor
Neuropathic pain sequelae
Randomized phase II trials
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
05 Dec 2022
05 Dec 2022
Historique:
received:
13
10
2022
accepted:
19
11
2022
entrez:
5
12
2022
pubmed:
6
12
2022
medline:
15
12
2022
Statut:
epublish
Résumé
Neuropathic pain is common in cancer survivorship and is one of the most distressing symptoms for patients previously treated for head and neck cancer. Persistent neuropathic pain, when it is ongoing and uncontrolled, has a detrimental effect and erodes patients' quality of life. Patients treated for head and neck cancer are chronic opioid users to manage their post-treatment pain, which may entail an increased risk of addiction and overdose. We propose to evaluate the analgesic activity of high-concentration capsaicin patches for the treatment of head and neck cancer survivors presenting with neuropathic pain sequelae. TEC-ORL is a parallel, multicenter randomized comparative phase II study evaluating whether Capsaïcin patches (Qutenza®) reduce neuropathic pain when compared to Amitriptyline (Laroxyl®) in head and neck cancer survivors presenting with neuropathic pain sequelae. The primary efficacy outcome is the rate of patients with a pain reduction of at least two points at 9 months compared to baseline. Assuming that 5% of patients become lost to follow-up, 130 patients will need to be randomized to detect a 25% improvement (i.e., standard: 25%, experimental: 50%) using a one-sided chi-square test with an alpha of 0.05%. According to the recommendations for comparative phase II trials, the target differences and type I error rates are relaxed. Randomized patients will either be treated with a capsaicin 8% (Qutenza®) patch applied at three time intervals in the experimental arm or with Amitriptyline (Laroxyl®) (oral solution 40 mg/ml) taken for 9 months at the recommended daily dose of 25 mg to 75 mg in the control arm. TEC-ORL is a randomized comparative phase II trial designed to comprehensively evaluate the analgesic activity of capsaicin compared to Laroxyl in Head and Neck Cancer survivors presenting with neuropathic pain sequelae. ClinicalTrials.gov identifier: NCT04704453 Date of registration: 2021/01/13.
Sections du résumé
BACKGROUND
BACKGROUND
Neuropathic pain is common in cancer survivorship and is one of the most distressing symptoms for patients previously treated for head and neck cancer. Persistent neuropathic pain, when it is ongoing and uncontrolled, has a detrimental effect and erodes patients' quality of life. Patients treated for head and neck cancer are chronic opioid users to manage their post-treatment pain, which may entail an increased risk of addiction and overdose. We propose to evaluate the analgesic activity of high-concentration capsaicin patches for the treatment of head and neck cancer survivors presenting with neuropathic pain sequelae.
METHODS
METHODS
TEC-ORL is a parallel, multicenter randomized comparative phase II study evaluating whether Capsaïcin patches (Qutenza®) reduce neuropathic pain when compared to Amitriptyline (Laroxyl®) in head and neck cancer survivors presenting with neuropathic pain sequelae. The primary efficacy outcome is the rate of patients with a pain reduction of at least two points at 9 months compared to baseline. Assuming that 5% of patients become lost to follow-up, 130 patients will need to be randomized to detect a 25% improvement (i.e., standard: 25%, experimental: 50%) using a one-sided chi-square test with an alpha of 0.05%. According to the recommendations for comparative phase II trials, the target differences and type I error rates are relaxed. Randomized patients will either be treated with a capsaicin 8% (Qutenza®) patch applied at three time intervals in the experimental arm or with Amitriptyline (Laroxyl®) (oral solution 40 mg/ml) taken for 9 months at the recommended daily dose of 25 mg to 75 mg in the control arm.
DISCUSSION
CONCLUSIONS
TEC-ORL is a randomized comparative phase II trial designed to comprehensively evaluate the analgesic activity of capsaicin compared to Laroxyl in Head and Neck Cancer survivors presenting with neuropathic pain sequelae.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov identifier: NCT04704453 Date of registration: 2021/01/13.
Identifiants
pubmed: 36471253
doi: 10.1186/s12885-022-10348-2
pii: 10.1186/s12885-022-10348-2
pmc: PMC9720988
doi:
Substances chimiques
Amitriptyline
1806D8D52K
Analgesics
0
Capsaicin
S07O44R1ZM
Banques de données
ClinicalTrials.gov
['NCT04704453']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1260Informations de copyright
© 2022. The Author(s).
Références
J Pain Symptom Manage. 2016 Jun;51(6):1070-1090.e9
pubmed: 27112310
Drugs. 2018 Sep;78(14):1489-1500
pubmed: 30251173
Head Neck Oncol. 2009 Jul 14;1:26
pubmed: 19594943
Stat Med. 2012 Feb 20;31(4):328-40
pubmed: 22139891
Pain. 2014 Oct;155(10):2171-9
pubmed: 25168665
J Clin Oncol. 2010 Apr 10;28(11):1936-41
pubmed: 20212253
J Clin Oncol. 2019 Jan 10;37(2):135-143
pubmed: 30457920
Eur Ann Otorhinolaryngol Head Neck Dis. 2014 Sep;131(4):243-7
pubmed: 25108356
Expert Rev Clin Pharmacol. 2016 Nov;9(11):1399-1402
pubmed: 27659719
JAMA Oncol. 2018 Jun 1;4(6):870-872
pubmed: 29621378
Pain. 2004 Apr;108(3):248-257
pubmed: 15030944
Cephalalgia. 2015 May;35(6):545-50
pubmed: 25217483
Schmerz. 2018 Dec;32(6):464-467
pubmed: 30306307
Cochrane Database Syst Rev. 2017 Jan 13;1:CD007393
pubmed: 28085183
Eur J Pain. 2019 May;23(5):908-922
pubmed: 30620116
Lancet Neurol. 2015 Feb;14(2):162-73
pubmed: 25575710
Nat Rev Dis Primers. 2017 Feb 16;3:17002
pubmed: 28205574
Otolaryngol Head Neck Surg. 2018 Nov;159(5):853-858
pubmed: 29943677
Laryngoscope. 2019 Sep;129(9):2087-2093
pubmed: 30613983
Pain Res Manag. 2019 May 6;2019:9675654
pubmed: 31198479